David Chang is President and Chief Executive Officer of Allogene Therapeutics, Inc. (ALLO). The company reported total compensation of $6,136,093 for fiscal year 2025.
| Salary | $724,000 |
|---|---|
| Bonus | — |
| Stock awards | $2,409,537 |
| Option awards | $2,588,329 |
| Non-equity incentive plan | $400,010 |
| Pension and non-qualified deferred compensation | — |
| All other compensation | $14,217 |
| Total | $6,136,093 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Allogene Therapeutics, Inc. filed April 30, 2026, accession 0001628280-26-028948.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $724,000 | — | $2,409,537 | $2,588,329 | $400,010 | — | $14,217 | $6,136,093 |
| FY2024 | President and Chief Executive Officer | $724,000 | $0 | $1,016,960 | $2,401,683 | $329,420 | $0 | $10,145 | $4,482,208 |
Totals as disclosed in each year's own compensation disclosure for Allogene Therapeutics, Inc..
| Peer-group chief executive median | $4,661,136 |
|---|---|
| Difference from that median | $1,474,958 |
| Percentile within the disclosed peer group | 85th |
| Peers with a disclosed figure | 19 |
Medians and percentiles are computed across the peer group Allogene Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Chang this page | President and Chief Executive Officer | $6,136,093 |
| Zachary Roberts | Chief Medical Officer and Executive Vice President of Research and Development | $1,987,723 |
| Geoffrey Parker | Executive Vice President and Chief Financial Officer | $1,943,962 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Allogene Therapeutics, Inc. compensation brief.
David Chang's compensation sits inside Allogene Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.